The blood-brain barrier is disrupted in a mouse model of infantile neuronal ceroid lipofuscinosis: amelioration by resveratrol
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Disruption of the blood-brain barrier (BBB) is a serious complication frequently encountered in neurodegenerative disorders. Infantile neuronal ceroid lipofuscinosis (INCL) is a devastating childhood neurodegenerative lysosomal storage disorder caused by palmitoyl-protein thioesterase-1 (PPT1) deficiency. It remains unclear whether BBB is disrupted in INCL and if so, what might be the molecular mechanism(s) of this complication. We previously reported that the Ppt1-knockout (Ppt1-KO) mice that mimic INCL manifest high levels of oxidative stress and neuroinflammation. Recently, it has been reported that CD4(+) T-helper 17 (T(H)17) lymphocytes may mediate BBB disruption and neuroinflammation, although the precise molecular mechanism(s) remain unclear. We sought to determine: (i) whether the BBB is disrupted in Ppt1-KO mice, (ii) if so, do T(H)17-lymphocytes underlie this complication, and (iii) how might T(H)17 lymphocytes breach the BBB. Here, we report that the BBB is disrupted in Ppt1-KO mice and that T(H)17 lymphocytes producing IL-17A mediate disruption of the BBB by stimulating production of matrix metalloproteinases (MMPs), which degrade the tight junction proteins essential for maintaining BBB integrity. Importantly, dietary supplementation of resveratrol (RSV), a naturally occurring antioxidant/anti-inflammatory polyphenol, markedly reduced the levels of T(H)17 cells, IL-17A and MMPs, and elevated the levels of tight junction proteins, which improved the BBB integrity in Ppt1-KO mice. Intriguingly, we found that RSV suppressed the differentiation of CD4(+) T lymphocytes to IL-17A-positive T(H)17 cells. Our findings uncover a mechanism by which T(H)17 lymphocytes mediate BBB disruption and suggest that small molecules such as RSV that suppress T(H)17 differentiation are therapeutic targets for neurodegenerative disorders such as INCL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kebir, H., Kreymborg, K., Ifergan, I., Dodelet-Devillers, A., Cayrol, R., Bernard, M., Giuliani, F., Arbour, N., Becher, B., & Prat, A. (2007) · Nature Medicine · doi:10.1038/nm1651 · Cited by 1,759 · cited 3×
“While TH17 lymphocytes have been implicated in mediating BBB disruption and neuroinflammation (4), the molecular mechanism(s), until now, remain unclear.”
BackgroundInfluentialFunctional Specialization of Interleukin-17 Family Members
Iwakura, Y., Ishigame, H., Saijo, S., & Nakae, S. (2011) · Immunity · doi:10.1016/j.immuni.2011.02.012 · Cited by 1,289
TH17 cells in development: an updated view of their molecular identity and genetic programming
Dong, C. (2008) · Nature reviews. Immunology · doi:10.1038/nri2295 · Cited by 1,064 · cited 1×
“Since IL-17A is produced by TH17 lymphocytes (1,16,17), we determined IL-17A levels in the blood and in the brains of WT mice and those of their Ppt1-KO littermates.”
BackgroundBlood–brain Barrier: Structural Components and Function Under Physiologic and Pathologic Conditions
Persidsky, Y., Ramirez, S. H., Haorah, J., & Kanmogne, G. D. (2006) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-006-9025-3 · Cited by 922 · cited 1×
“The tight junctions between adjacent endothelial cells provide a metabolic and physical barrier, which selectively allows movement of macromolecules between the blood and the brain (13,14) in order to maintain homeostasis.”
BackgroundGenome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells
Zheng, Y., Josefowicz, S. Z., Kas, A., Chu, T.-T., Gavin, M. A., & Rudensky, A. Y. (2007) · Nature · doi:10.1038/nature05563 · Cited by 835
Matrix metalloproteinases and their multiple roles in neurodegenerative diseases
Rosenberg, G. A. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70016-x · Cited by 594
Lochhead, J. J., McCaffrey, G., Quigley, C. E., Finch, J., DeMarco, K. M., Nametz, N., & Davis, T. P. (2010) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.29 · Cited by 334 · cited 1×
“Furthermore, it has been reported that both oxidative stress (28) and neuroinflammation (22) contribute to BBB disruption (29).”
Background
Cited by
Blood–brain barrier structure and function and the challenges for CNS drug delivery
Abbott, N. J. (2013) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-013-9608-0 · Cited by 909
Polyphenols: Multipotent Therapeutic Agents in Neurodegenerative Diseases
Bhullar, K. S., & Rupasinghe, H. P. V. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/891748 · Cited by 411
The pharmacology of resveratrol in animals and humans
Park, E.-J., & Pezzuto, J. M. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.01.014 · Cited by 302
Rahman, M. H., Bajgai, J., Fadriquela, A., Sharma, S., Trinh, T. T., Akter, R., Jeong, Y. J., Goh, S. H., Kim, C.-S., & Lee, K.-J. (2021) · Molecules · doi:10.3390/molecules26175327 · Cited by 182
Resveratrol Brain Delivery for Neurological Disorders Prevention and Treatment
Andrade, S., Ramalho, M. J., Pereira, M. D. C., & Loureiro, J. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01261 · Cited by 173
Metadata
- Authors
- Saha, A., Sarkar, C., Singh, S. P., Zhang, Z., Munasinghe, J., Peng, S., Chandra, G., Kong, E., & Mukherjee, A. B.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-02-13
- Volume
- 21
- Issue
- 10
- Pages
- 2233-2244
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2104551034
- Cited by
- 63
- References
- 7
- FWCI
- 3.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.